9.34
0.10 (1.08%)
| Previous Close | 9.24 |
| Open | 9.34 |
| Volume | 1,691,868 |
| Avg. Volume (3M) | 2,499,268 |
| Market Cap | 1,508,226,688 |
| Price / Earnings (Forward) | 22.17 |
| Price / Sales | 5.15 |
| Price / Book | 3.34 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2025 |
| Profit Margin | -20.25% |
| Operating Margin (TTM) | -5.14% |
| Diluted EPS (TTM) | -0.290 |
| Quarterly Revenue Growth (YOY) | 47.90% |
| Current Ratio (MRQ) | 1.72 |
| Operating Cash Flow (TTM) | -26.71 M |
| Levered Free Cash Flow (TTM) | -5.90 M |
| Return on Assets (TTM) | -3.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Xeris Biopharma Holdings, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.19% |
| % Held by Institutions | 54.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Parkman Healthcare Partners Llc | 30 Jun 2025 | 2,107,483 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 7.07%) | Buy |
| Median | 9.50 (1.71%) | |
| Low | 9.00 (Leerink Partners, -3.64%) | Buy |
| Average | 9.50 (1.71%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 19 Aug 2025 | 9.00 (-3.64%) | Buy | 7.36 |
| HC Wainwright & Co. | 12 Aug 2025 | 10.00 (7.07%) | Buy | 7.30 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Oct 2025 | Announcement | Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 25 Aug 2025 | Announcement | Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® |
| 07 Aug 2025 | Announcement | Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance |
| 31 Jul 2025 | Announcement | Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |